“Sleepiness” in obstructive sleep apnea: getting into deep water

Kallweit, Ulf; Pevernagie, Dirk; Lammers, Gert Jan

doi:10.1016/j.sleep.2022.02.015

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive daytime sleepiness (EDS)/fatigue: 5-10% of OSA patients, who are under effective PAP treatment, still describe EDS [43]. This condition often is called "residual EDS (R-EDS) in OSA".…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pharmacological Treatments of Sleep–Wake Disorders: Update 2023

Kallweit,

Kallweit

2023

CTN

Self Cite

View full text Add to dashboard Cite

Biological, environmental, behavioral, and social factors can influence sleep and lead to sleep disorders or diseases. Sleep disorders are common, numerous, and heterogeneous in terms of their etiology, pathogenesis, and symptomatology. The management of sleep–wake circadian disorders (SWCDs) includes education on sleep hygiene, behavioral strategies, psychotherapy (cognitive behavioral therapy (CBT), particularly), instrument-based treatments (i.e., positive airway pressure therapy, hypoglossal nerve stimulation), and pharmacotherapy. Depending on the disease, therapy varies and is executed sequentially or can be a combination of several forms of therapy. Drugs used for SWCDs include traditional sleep- or wake-promoting agents and chronotherapeutic agents. Recently, novel medications, which more precisely act on specific neurochemical systems (i.e., the orexin system) important for sleep and waking, are also increasingly being used. In this review, the pharmacotherapy of common sleep disorders (insomnia, sleep-related breathing disorder, central disorders of hypersomnolence, circadian rhythm sleep–wake disorders, parasomnias, and sleep-related movement disorders) embedded in the overall therapeutic concept of each disorder is presented. There is also an outlook on possible future pharmacotherapies.

show abstract

mentioning

confidence: 99%

“…The daytime symptomatology, however, still needs further differentiation (EDS vs. fatigue vs. cognitive disturbances). Further, it remains unclear whether EDS is the consequence of OSA at all [43]. In the last decades, modafinil (off-label in the EU) and armodafinil have been used for the treatment of persistent EDS in OSA.…”

mentioning

confidence: 99%

Pharmacological Treatments of Sleep–Wake Disorders: Update 2023

Kallweit,

Kallweit

2023

CTN

Self Cite

View full text Add to dashboard Cite

show abstract

Pharmacological Treatments of Sleep-Wake Disorders: Update 2023

Kallweit,

Kallweit

2023

Preprint

View full text Add to dashboard Cite

Biological, environmental, behavioral, and social factors can influence sleep and lead to sleep disorders or diseases. Sleep disorders are common, numerous and heterogeneous in terms of their etiology, pathogenesis, and symptomatology. Management of sleep-wake circadian disorders (SWCD) includes education to sleep hygiene, behavioral strategies, psychotherapy (cognitive behavioral therapy (CBT), particularly), instrument-based treatments (i.e. positive airway pressure therapy, hypoglossal nerve stimulation), and pharmacotherapy. Depending on the disease, therapy varies and is executed sequentially, or can be a combination of several forms of therapy. Drugs used for SWCD include traditional sleep or wake-promoting agents, chronotherapeutic agents. Recently, novel medications, which are more precisely acting on specific neurochemical systems (i.e. orexin system) important for sleep and wake, are also increasingly being used. In this review, the pharmacotherapy of common sleep disorders (insomnia, sleep-related breathing disorder, central disorders of hypersomnolence, circadian rhythm sleep wake disorders, parasomnias, and sleep-related movement disorders) embedded in the overall therapeutic concept of each disorder is presented. There is also an outlook on possible future pharmacotherapies.

show abstract

“Sleepiness” in obstructive sleep apnea: getting into deep water

Cited by 2 publications

References 21 publications

Pharmacological Treatments of Sleep–Wake Disorders: Update 2023

Pharmacological Treatments of Sleep–Wake Disorders: Update 2023

Pharmacological Treatments of Sleep-Wake Disorders: Update 2023

Contact Info

Product

Resources

About